Department of Medical Microbiology, University Medical Center Utrecht, Utrecht University, Utrecht, the Netherlands.
Julius Center for Health Sciences and Primary Care, University Medical Center Utrecht, Utrecht University, Utrecht, the Netherlands.
J Immunol. 2024 Dec 1;213(11):1644-1655. doi: 10.4049/jimmunol.2300858.
Staphylococcus aureus is the major cause of healthcare-associated infections, including life-threatening conditions as bacteremia, endocarditis, and implant-associated infections. Despite adequate antibiotic treatment, the mortality of S. aureus bacteremia remains high. This calls for different strategies to treat this infection. In past years, sequencing of Ab repertoires from individuals previously exposed to a pathogen emerged as a successful method to discover novel therapeutic monoclonal Abs and understand circulating B cell diversity during infection. In this paper, we collected peripheral blood from 17 S. aureus bacteremia patients to study circulating plasmablast responses. Using single-cell transcriptome gene expression combined with sequencing of variable heavy and light Ig genes, we retrieved sequences from >400 plasmablasts revealing a high diversity with >300 unique variable heavy and light sequences. More than 200 variable sequences were synthesized to produce recombinant IgGs that were analyzed for binding to S. aureus whole bacterial cells. This revealed four novel monoclonal Abs that could specifically bind to the surface of S. aureus in the absence of Ig-binding surface SpA. Interestingly, three of four mAbs showed cross-reactivity with Staphylococcus epidermidis. Target identification revealed that the S. aureus-specific mAb BC153 targets wall teichoic acid, whereas cross-reactive mAbs BC019, BC020, and BC021 target lipoteichoic acid. All mAbs could induce Fc-dependent phagocytosis of staphylococci by human neutrophils. Altogether, we characterize the active B cell responses to S. aureus in infected patients and identify four functional mAbs against the S. aureus surface, of which three cross-react with S. epidermidis.
金黄色葡萄球菌是医疗保健相关感染的主要原因,包括危及生命的感染,如菌血症、心内膜炎和植入物相关感染。尽管进行了适当的抗生素治疗,金黄色葡萄球菌菌血症的死亡率仍然很高。这就需要采取不同的策略来治疗这种感染。在过去的几年中,对先前接触过病原体的个体的 Ab 库进行测序已成为发现新型治疗性单克隆抗体和了解感染过程中循环 B 细胞多样性的成功方法。在本文中,我们从 17 名金黄色葡萄球菌菌血症患者收集外周血,以研究循环浆细胞反应。使用单细胞转录组基因表达结合可变重链和轻链 Ig 基因测序,我们从>400 个浆细胞中检索到序列,揭示了高度多样性,有>300 个独特的可变重链和轻链序列。合成了 200 多个可变序列以产生重组 IgG,并分析其与金黄色葡萄球菌全细菌细胞的结合。这揭示了四种新型单克隆抗体,它们可以在没有 Ig 结合表面 SpA 的情况下特异性结合金黄色葡萄球菌表面。有趣的是,四种 mAb 中有三种与表皮葡萄球菌具有交叉反应性。靶标鉴定表明,金黄色葡萄球菌特异性 mAb BC153 靶向壁磷壁酸,而交叉反应性 mAb BC019、BC020 和 BC021 靶向脂磷壁酸。所有 mAb 均可诱导人中性粒细胞通过 Fc 依赖性吞噬作用吞噬葡萄球菌。总之,我们描述了感染患者中针对金黄色葡萄球菌的活性 B 细胞反应,并鉴定了四种针对金黄色葡萄球菌表面的功能性 mAb,其中三种与表皮葡萄球菌交叉反应。